Predictive biomarkers will be increasingly important to enhance survival rates and to develop competitive services for patients with cancer. Therefore, guidelines are needed for the incorporation of biomarkers into routine clinical practice. Our aim is to improve therapeutic strategies by the evaluation of personalised medicine using an omics-based approach. The overall goal of this project is to support high priority hypothesis-testing biomarker evaluations through the analysis and development of a biomarker-portfolio in acute myeloblastic leukemia, melanoma, neuroblastoma and ovarian cancer using 1- targeted enrichment sequencing panels for each model; 2- study of the exome, transcriptome and methyloma of specific subgroups of patients defined by combination or exclusion of major mutations for the four disease models; 3- integration for the development of biological signatures a) to select patients for new treatment strategies (‘predictive biomarkers’) and (b) for risk stratification (‘prognostic biomarkers’); 4- study of the expression profile of miRNAs in plasma involved in angiogenesis alterations associated with cancer, and identify their target genes and pathways; 5- development of a pharmacogenetic model based on the selection of SNPs and subsequent genotyping in the 4 models of disease including SNPs previously described in the literature and other SNPs in candidate genes and 6- testing the cancer promoting role of novel mutations by the use of CRISPR genome-editing tool and exploring the potential therapeutic capacity of this technology.